LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

Search

PerkinElmer Inc

Închisă

SectorSănătate

0

Rezumat

Modificarea prețului

24h

Curent

Minim

Maxim

Indicatori cheie

By Trading Economics

Venit

-52M

42M

Vânzări

-65M

665M

P/E

Medie Sector

38.519

54.379

EPS

1.01

Randament dividend

0.3

Marjă de profit

6.354

Angajați

11,000

EBITDA

-151M

72M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+28.92% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.30%

2.55%

Următoarele câștiguri

28 iul. 2025

Data viitoare de dividende

9 mai 2025

Următoarea dată ex-dividende

18 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-2.8B

11B

Deschiderea anterioară

0

Închiderea anterioară

0

Sentimentul știrilor

By Acuity

35%

65%

134 / 382 Clasament în Healthcare

PerkinElmer Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

8 mai 2025, 23:59 UTC

Top știri
Câștiguri

Naver 1Q Net Slumps on Higher Costs

8 mai 2025, 23:39 UTC

Câștiguri

OCBC 1Q Net Down on Lower Interest Income

8 mai 2025, 23:01 UTC

Câștiguri

Macquarie Raises Dividend After 5.5% Rise in Annual Profit -- Update

8 mai 2025, 22:52 UTC

Câștiguri

REA Expects Annual Listings Growth Despite April Decline

8 mai 2025, 22:46 UTC

Câștiguri

Macquarie Raises Dividend After 5.5% Rise in Annual Profit

8 mai 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

8 mai 2025, 23:45 UTC

Market Talk

Nikkei May Rise as Tariffs Fears Ease -- Market Talk

8 mai 2025, 23:41 UTC

Market Talk

Gold Rises on Possible Technical Recovery; Gains May be Capped by Risk-on Mood -- Market Talk

8 mai 2025, 23:30 UTC

Câștiguri

Itau Unibanco 1Q Rev BRL45.02B >ITUB

8 mai 2025, 23:29 UTC

Câștiguri

Itau Unibanco 1Q EPS BRL1.03 >ITUB

8 mai 2025, 23:22 UTC

Câștiguri

Naver 1Q Net Profit Largely Met FactSet-Compiled Consensus

8 mai 2025, 23:22 UTC

Câștiguri

Naver 1Q Net KRW423.70B Vs. Net KRW555.80B >035420.SE

8 mai 2025, 23:21 UTC

Câștiguri

Naver 1Q Oper Pft KRW505.30B Vs. Pft KRW439.30B >035420.SE

8 mai 2025, 23:21 UTC

Câștiguri

Naver 1Q Rev KRW2.787T Vs. KRW2.526T >035420.SE

8 mai 2025, 23:17 UTC

Câștiguri

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.35B Vs. S$2.44B >O39.SG

8 mai 2025, 23:17 UTC

Câștiguri

Oversea-Chinese Banking Corp. 1Q Total Income S$3.66B Vs. S$3.63B >O39.SG

8 mai 2025, 23:17 UTC

Câștiguri

Oversea-Chinese Banking Corp. 1Q Net S$1.88B Vs. Net S$1.98B >O39.SG

8 mai 2025, 23:05 UTC

Market Talk

ANZ Could Cut Dividend by 10% From 2H -- Market Talk

8 mai 2025, 23:05 UTC

Market Talk

Global Equities Roundup: Market Talk

8 mai 2025, 23:01 UTC

Top știri

With U.K. Deal, U.S. Signals That 10% Tariff on World Is New Baseline -- WSJ

8 mai 2025, 22:28 UTC

Câștiguri

REA Expects FY 2025 Listings Growth of 1-2%

8 mai 2025, 22:28 UTC

Câștiguri

REA Says April Listings Decline Reflects Year Ago Strength, Timing of Easter and Election

8 mai 2025, 22:27 UTC

Câștiguri

REA Says April Sydney, Melbourne Listings Both Down 16% on Year

8 mai 2025, 22:27 UTC

Câștiguri

REA Says April Residential Listings Fell by 11% on Year

8 mai 2025, 22:26 UTC

Câștiguri

REA 3Q Operating Expenses A$176 Million, Up 12% on Year

8 mai 2025, 22:26 UTC

Câștiguri

REA 3Q Free Cash Flow A$132 Million, Up 19% on Year

8 mai 2025, 22:26 UTC

Câștiguri

REA 3Q Operating Ebitda A$199 Million, Up 12% on Year

8 mai 2025, 22:26 UTC

Câștiguri

REA Nine-Months Free Cash Flow A$389 Million, Up 21% on Year

8 mai 2025, 22:25 UTC

Câștiguri

REA Nine-Months Operating Expenses A$513 Million, Up 15% on Year

8 mai 2025, 22:25 UTC

Câștiguri

REA Nine-Months Operating Ebitda A$734 Million, Up 19% on Year

Comparație

Modificare preț

PerkinElmer Inc Așteptări

Obiectiv de preț

By TipRanks

28.92% sus

Prognoză pe 12 luni

Medie 118.08 USD  28.92%

Maxim 135 USD

Minim 100 USD

În baza a 14 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruPerkinElmer Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

14 ratings

9

Cumpărare

5

Păstrare

0

Vânzare

Sentiment

By Acuity

134 / 382 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.